NCTRC and Icon will work together on study startup, site feasibility, key site and investigator selection and patient recruitment. Both organizations will also work together on further enhancing the already high standards of clinical research in Taiwan.
“The aim of this partnership is to accelerate new drug development and new treatments for diseases and we hope to achieve this by leveraging our respective strengths,” said professor Chan Wing Kai, director of NCTRC.
